Astria Therapeutics (ATXS)
(Delayed Data from NSDQ)
$9.47 USD
+0.46 (5.11%)
Updated May 31, 2024 04:00 PM ET
After-Market: $9.48 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Astria Therapeutics, Inc. [ATXS]
Reports for Purchase
Showing records 1 - 20 ( 69 total )
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Keep On Moving Forward - STAR-0215 Remains On Track [1Q24 Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Right Answers in Hand; Now Need Time; Target Adjusted Down to $16
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hitching Our Wagon To ALPHA-STAR; Increasing Target to $22
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Optimism Builds For STAR-0215 in HAE; Positive Initial Phase 1b/2 Data Set Stage For Upcoming Pivotal Studies in 2025
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
As We Await a First Look at Phase 1b/2 ALPHA-STAR Data in HAE Patients, Where Does STAR-0215 Stand?
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; All Eyes on Imminent ALPHA-STAR Proof-of-Concept Data in HAE Patients
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- HAE KOL Call Check: Revisiting The Therapeutic Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Wishing On A STAR(-0215): Revisiting The ALPHA-STAR Readout
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
INVITE: HAE KOL Call -- Revisiting the HAE Treatment Landscape
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Updated Timelines Bring STAR-0215 Closer to Finish Line; Initial ALPHA-STAR Readout Expected 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Quarter Of Execution As We Await STAR-0215 Proof-of- Concept Data
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Astria Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Little Goes a Long Way; Updated Phase 1a Data Strengthen STAR-0215''s Profile For Long-Term Dosing
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J